BNP Paribas Financial Markets
ZYNE

BNP Paribas Financial Markets’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

BNP Paribas Financial Markets’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-29,789
Closed -$85.8K – 4413
2021
Q4 		$85.8K Buy
+29,789
New +$110K ﹤0.01% 3641
2021
Q3 		– Sell
-16
Closed -$85 – 4111
2021
Q2 		$85 Hold
16
– – ﹤0.01% 4011
2021
Q1 		$74 Hold
16
– – ﹤0.01% 3958
2020
Q4 		$53 Hold
16
– – ﹤0.01% 4085
2020
Q3 		$53 Sell
16
-51,586
-100% -$189K ﹤0.01% 4138
2020
Q2 		$174K Buy
51,602
+44,507
+627% +$210K ﹤0.01% 2552
2020
Q1 		$27.2K Buy
7,095
+3,793
+115% +$17.6K ﹤0.01% 3815
2019
Q4 		$19.9K Buy
3,302
+655
+25% +$4.48K ﹤0.01% 4010
2019
Q3 		$20K Buy
2,647
+2,588
+4,386% +$29.2K ﹤0.01% 3949
2019
Q2 		$799 Sell
59
-206
-78% -$2.38K ﹤0.01% 4379
2019
Q1 		$1.44K Hold
265
– – ﹤0.01% 4133
2018
Q4 		$787 Sell
265
-6
-2% -$33 ﹤0.01% 3953
2018
Q3 		$2.21K Hold
271
– – ﹤0.01% 4244
2018
Q2 		$2.64K Sell
271
-2,299
-89% -$23.6K ﹤0.01% 4222
2018
Q1 		$22.3K Buy
2,570
+50
+2% +$539 ﹤0.01% 3901
2017
Q4 		$31.6K Buy
2,520
+1,407
+126% +$16.1K ﹤0.01% 3859
2017
Q3 		$9.3K Sell
1,113
-82
-7% -$867 ﹤0.01% 3890
2017
Q2 		$20.3K Buy
1,195
+1,194
+119,400% +$23.7K ﹤0.01% 3654
2017
Q1 		$20 Hold
1
– – ﹤0.01% 4048
2016
Q4 		$16 Hold
1
– – ﹤0.01% 4140
2016
Q3 		$13 Hold
1
– – ﹤0.01% 3526
2016
Q2 		$7 Sell
1
-56
-98% -$469 ﹤0.01% 3550
2016
Q1 		$539 Sell
57
-583
-91% -$4.7K ﹤0.01% 2553
2015
Q4 		$6.44K Hold
640
– – ﹤0.01% 3440
2015
Q3 		$9.16K Buy
+640
New +$15.7K ﹤0.01% 3435

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BNP Paribas Financial Markets's ZYNE Position: Q1 2022 in Review

BNP Paribas Financial Markets sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 29,789 shares — an estimated $85.8K sold.

BNP Paribas Financial Markets first reported a position in ZYNE in Q3 2015 and held it in 25 quarters. The position peaked at $174K in Q2 2020. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

  • BNP Paribas Financial Markets reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 29,789 Zynerba Pharmaceuticals, Inc shares in Q1 2022, an estimated $85.8K.
  • BNP Paribas Financial Markets first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 25 quarters.
  • BNP Paribas Financial Markets's Zynerba Pharmaceuticals, Inc position peaked at $174K in Q2 2020.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2022, filed 17 May 2022.